Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

Hill, Andrew G.; Findlay, Michael P.; Burge, Matthew E.; Jackson, Christopher; Garcia Alfonso, Pilar; Samuel, Leslie; Ganju, Vinod; Karthaus, Meinolf; Amatu, Alessio; Tabernero, Josep

Inicio
→
Recerca
→
Articles, congressos, llibres
→
Articles
→
Ver ítem

dc.contributor	Vall d'Hebron Institut d'Oncologia
dc.contributor.author	Hill, Andrew G.
dc.contributor.author	Findlay, Michael P.
dc.contributor.author	Burge, Matthew E.
dc.contributor.author	Jackson, Christopher
dc.contributor.author	Garcia Alfonso, Pilar
dc.contributor.author	Samuel, Leslie
dc.contributor.author	Ganju, Vinod
dc.contributor.author	Karthaus, Meinolf
dc.contributor.author	Amatu, Alessio
dc.contributor.author	Tabernero, Josep
dc.date.accessioned	2024-01-31T16:16:18Z
dc.date.available	2024-01-31T16:16:18Z
dc.date.created	2018
dc.date.issued	2018
dc.identifier.citation	Hill, A. G., Findlay, M. P., Burge, M. E., Jackson, C., Alfonso, P. G., Samuel, L., . . . Tabernero, J. (2018). Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research, 24(10), 2276-2284. https://doi.org/10.1158/1078-0432.ccr-17-0646	es
dc.identifier.issn	1078-0432
dc.identifier.uri	http://hdl.handle.net/10854/7724
dc.description.abstract	Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerable toxicity. Mandatory tumor samples underwent mutation and biomarker analysis. Efficacy analysis was conducted in patients with RAS exon 2/3 wild-type tumors. Results: Of 134 randomly assigned patients, 98 had RAS ex2/3 wild-type. Duligotuzumab provided no progression-free survival (PUS) or overall survival (OS) benefit compared with cetuximab, although there was a trend for a lower objective response rate (ORR) in the duligotuzumab arm. No relationship was seen between HS or ORR and ERBB3, NRC1, or AREC expression. it were fewer skin rash events for duligotuzumab but more diarrhea. Although the incidence of grade >= 3 AEs was similar, the frequency of serious ALs was higher for duligotuzumab. Conclusions: Duligotuzumab plus FOLFIRI did not appear to improve the outcomes in patients with RAS exon 2/3 wild-type mCRC compared with cetuximab + FOLHRI. (C) 2018 AACR.	es
dc.description.sponsorship	The authors wish many thanks to all of the patients and the investigators who participated in this study. Writing assistance was provided by Genentech, Inc. This work was supported by Genentech, Inc.	EN
dc.format	application/pdf	es
dc.format.extent	9 p.	es
dc.language.iso	eng	es
dc.publisher	American Association Cancer Research	es
dc.rights	Aquest document està subjecte a aquesta llicència Creative Commons	es
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/deed.ca	es
dc.subject.other	Medicaments -- Assaigs clínics	es
dc.subject.other	Recte -- Càncer	es
dc.subject.other	Metàstasi	es
dc.title	Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer	es
dc.type	info:eu-repo/semantics/article	es
dc.identifier.doi	https://doi.org/10.1158/1078-0432.ccr-17-0646
dc.rights.accessRights	info:eu-repo/semantics/openAccess	es
dc.type.version	info:eu-repo/acceptedVersion	es
dc.indexacio	Indexat a WOS/JCR	es
dc.indexacio	Indexat a SCOPUS	es